Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award will be announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies, including Baillie Gifford (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, have been awarded the title [1] Group 2: Evaluation Criteria - The evaluation for the award is based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were determined through quantitative data analysis and an expert review panel [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

Core Insights - The liquid cooling industry is transitioning from a "first development stage" focused on concepts and expectations to a "second development stage" characterized by order confirmations, capacity realization, and performance delivery [1][4] Group 1: Industry Transition - The liquid cooling system is moving towards performance realization, with high-power cabinets (100kW+) becoming the new norm, and the GB300 series AI servers expected to start mass production by the end of 2025 [2][4] - The market focus is shifting from discussions about liquid cooling concepts to actual performance metrics and market space evaluations, marking the end of the expectation-driven phase [1][2] Group 2: Competitive Landscape - The competitive landscape is evolving from individual component competition to a comprehensive thermal management system that spans servers, cabinets, and data center equipment, increasing customer reliance on solution providers [3][4] - Industry leaders are expected to benefit from their comprehensive solutions, large-scale delivery capabilities, and established relationships with major clients, reinforcing a "stronger gets stronger" dynamic in the market [3][4] Group 3: Market Opportunities - The liquid cooling market is being systematically re-evaluated as the application boundaries expand from GPU servers to switches and ASIC devices, indicating a significant growth potential [2][4] - Companies with full-stack solution capabilities and certifications from leading clients are positioned to capture the upcoming industry benefits, particularly those with extensive global delivery experience [4]

Investment Rating - The report maintains an "Overweight" rating for the non-ferrous metals sector [1] Core Views - The non-ferrous metals sector saw a weekly increase of 1.46%, ranking in the upper middle among all primary industries. The energy metals sector rose by 5.08%, while the precious metals sector increased by 0.68% [1][14] - Gold prices have broken through the consolidation range, while silver's bullish sentiment has peaked, indicating a potential risk of a sharp short-term correction [1][49][50] Summary by Sections Market Review - The Shanghai Composite Index rose by 0.33%, with the non-ferrous metals sector outperforming the index by 1.44 percentage points [14] - The report highlights the performance of various sub-sectors, with energy metals leading the gains [14] Industrial Metals - **Copper**: Prices fluctuated with LME copper at $11,882 per ton (up 2.85%) and SHFE copper at ¥93,180 per ton (down 0.96%). Supply remains weak, with a forecasted global copper shortage of 150,000 tons by 2026. Demand is deteriorating as construction projects pause, leading to increased spot market discounts [2][30] - **Aluminum**: LME aluminum rose to $2,945 per ton (up 2.43%), while SHFE aluminum was at ¥22,185 per ton (up 0.07%). Supply conditions are stable, with new capacity coming online, but demand remains cautious due to a downturn in the real estate sector [3][35] - **Zinc**: Prices fell, with LME zinc at $3,073 per ton (down 2.12%) and SHFE zinc at ¥23,065 per ton (down 2.29%). Inventory levels showed mixed trends [41] - **Tin**: Prices increased, with LME tin at $43,227 per ton (up 5.11%) and SHFE tin at ¥343,040 per ton (up 3.02%). Supply from Indonesia has increased, but demand remains cautious [46] Precious Metals - **Gold**: COMEX gold closed at $4,368.70 per ounce (up 0.90%), while SHFE gold was at ¥979.90 per gram (up 0.95%). Economic data from the U.S. showed mixed results, but overall inflation appears to be cooling, which may influence future gold prices positively [4][49] - **Silver**: The report warns of extreme bullish sentiment in silver, with potential for a sharp correction as market volatility peaks [50]

氯碱周报 S H ：需求端支撑乏力 ， 预计价格反弹后重回弱势 V ：供需仍存压力 ， 价格延续底部震荡 广发期货研究所 蒋诗语 投资咨询资格：Z0017002 本报告及路演当中所有观点仅供参考，请务必阅读此报告倒数第二页的免责声明 观点及策略建议 ◼ 烧碱主要观点：烧碱行业供需仍存一定压力，虽然部分区域企业库存去库，部分区域下游采买存积极性，但库存水平依然偏高，短期暂无明显利好显现，下周价格仍偏看空。 华东地区下周供应存恢复预期，供量增加下且需求未有实质性改善，预估下周华东区域液碱价格延续弱行。山东地区需求端利好尚未显现，企业开工高位维持，出货情况一般，预 计整体山东市场弱势维持。整体看需求端支撑较弱，长期看供需仍有压力。预计烧碱价格偏弱运行。 ◼ 期货策略建议：偏空思路 ◼ 期权策略建议：暂观望 ◼ PVC主要观点：供应端本周压力不减，但受到海外装置停产提振盘面大幅反弹。下周开工率预计小幅下降，需求端内外存压，持续低迷，淡季下硬制品开工低位，软制品相对稳 定。成本端支撑预期松动，预期PVC市场继续维持区间整理运行。当前处于传统需求淡季，北方进入冬季室外施工逐渐减少，整体地产需求减量仍形成利空影响。出口方面 ...

Core Viewpoint - Dongyangguang Pharmaceutical Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone in the company's history and a breakthrough for Chinese innovative pharmaceutical companies in asset securitization and internationalization [1] Company Overview - Dongyangguang Pharmaceutical is a comprehensive pharmaceutical company engaged in drug research, production, and commercialization, founded in 2003 with a mission to improve human life quality and health through scientific research [3] - The company focuses on three major areas: infections, chronic diseases, and tumors, with a research team of over 1,100 people, ranking among the top tier in domestic R&D capabilities [3] - Dongyangguang has over 150 approved drugs globally, nearly 50 innovative drugs in development, with 3 original innovative drugs approved for market, 1 pending approval, and 10 in clinical phases II and III, many of which have "First in class" or "Best in class" potential [3] Recent Developments - The company has applied for over 2,500 invention patents and has received multiple high-level honors, including the National Key Laboratory for New Drug Research and Development in Anti-infection and the Guangdong Provincial Science and Technology Progress Award [3] - The company has made significant international breakthroughs, with its innovative drug HEC88473 set for overseas authorization in 2024 and insulin glargine completing registration in the United States [3] - Dongyangguang has established a global sales network, with its core product, Kewai, becoming the leading domestic brand for anti-influenza drugs [3] Industry Context - The timing of Dongyangguang's listing is favorable, as the innovative drug policy benefits have been released intensively this year, leading the industry into a high-growth phase [4] - In the first half of this year, the Hong Kong stock market saw significant breakthroughs in the number of pharmaceutical IPOs and total fundraising, with the biopharmaceutical sector raising HKD 15.6 billion and 10 biopharmaceutical companies successfully listing, nearing the total for the entire year of 2024 [4] - With ongoing policy deepening, a group of Chinese innovative pharmaceutical companies, exemplified by Dongyangguang, is expected to occupy a more significant position in the global market [4]

Core Viewpoint - The National Medical Products Administration (NMPA) has rejected 118 drug listing applications over three days, including 13 first-generic products, indicating a trend towards stricter drug approval processes [1][27]. Group 1: Drug Approval Rejections - The NMPA denied applications for several first-generic drugs, including indomethacin gel patches from Jiutian Pharmaceutical and meloxicam nano-crystal injections from Health元药业 [1][27]. - The rejection of these applications poses a risk to pharmaceutical companies that have made significant investments in these products [1][27]. Group 2: Market Impact and Competition - Jiutian Pharmaceutical, known for its core product, the Loxoprofen sodium gel patch, faced a setback with its indomethacin gel patch application, which had a market share of only 0.16% compared to Nipro Pharma's indomethacin patch, which has over 45% market share and annual sales exceeding 110 million yuan [4][10]. - Four companies have submitted applications for the indomethacin gel patch, with three already receiving clinical approval, indicating a competitive landscape [5][10]. Group 3: Other Drug Applications - Other first-generic applications, such as for bilastine oral solution and brivaracetam orally disintegrating tablets, were also rejected, reflecting the stringent review process [1][27]. - The market for amlodipine besylate, a cornerstone drug for hypertension, remains strong, with sales exceeding 3.6 billion yuan in 2024, despite the influx of generic competitors [11][14]. Group 4: Future Opportunities - The failure of Jiutian Pharmaceutical and Dongyangguang Pharmaceutical in their respective applications highlights the need for companies to focus on quality and clinical needs rather than merely following trends in drug formulation [27]. - The approval of alternative formulations, such as the dry suspension and orally disintegrating tablets, suggests that there are still opportunities for innovation in the market [20][21].

Investment Rating - The report maintains a "Positive" investment rating for the Cordyceps industry, indicating optimism about its growth potential and market opportunities [2]. Core Insights - The Cordyceps industry is characterized by a market size exceeding 30 billion, with a gradual decline in natural production due to environmental changes and overharvesting. The demand for Cordyceps remains stable, while artificial cultivation technologies are advancing, potentially replacing some natural supply [6][7]. - The report highlights that artificial Cordyceps cultivation has made significant technological breakthroughs, allowing for standardized production and the potential to meet market demand more effectively [6][7]. Summary by Sections 1. Overview of Cordyceps - Cordyceps is a rare medicinal fungus primarily found in China, with over 98% of global production originating from the Tibetan Plateau. The natural growth cycle takes approximately 2-3 years [5][17]. - The fungus is known for its health benefits, including immune system regulation and anti-fatigue properties, making it a valuable medicinal resource [5][24]. 2. Industry Status - The natural production of Cordyceps has been declining, with current annual output around 200 tons, while the market size is estimated at approximately 30 billion. The main production areas are Qinghai and Tibet, which together account for over 80% of the total output [28][30]. - Historical data shows that production has decreased from over 1,000 tons in the 1950s to about 200 tons in the 21st century, with prices experiencing significant fluctuations over the decades [28][36]. 3. Artificial Cultivation - Recent advancements in artificial cultivation techniques have opened new avenues for production, with three main methods identified: factory-based cultivation simulating high-altitude conditions, artificial infection of adult insects followed by outdoor rearing, and semi-wild cultivation with minimal intervention [41][44]. - The report notes that while the industry is still in its early stages of industrialization, companies like Dongyangguang have successfully achieved stable production, with significant investments from other players like Zhongxing Junye [6][41]. 4. Competitive Landscape - The market is currently dominated by a few key players, with significant concentration of production capacity. Companies are actively investing in artificial cultivation, indicating a shift towards more sustainable supply sources [6][7]. - The report emphasizes that the entry of edible mushroom companies into the Cordyceps cultivation space is expected to enhance competition but will have a limited impact on pricing in the short term due to the high technical barriers [8].

证券之星消息，12月18日综合板块较上一交易日下跌1.27%，东阳光领跌。当日上证指数报收于 3876.37，上涨0.16%。深证成指报收于13053.98，下跌1.29%。综合板块个股涨跌见下表： 从资金流向上来看，当日综合板块主力资金净流出6824.68万元，游资资金净流出1153.77万元，散户资 金净流入7978.45万元。综合板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

Group 1 - The core viewpoint of the news is that Dongyangguang's stock has experienced fluctuations, with a year-to-date increase of 90.97% but a recent decline of 5.44% over the last five trading days [1] - As of December 18, Dongyangguang's stock price is 21.56 yuan per share, with a market capitalization of 64.886 billion yuan and a trading volume of 335 million yuan [1] - The company has seen a net outflow of 10.1135 million yuan in principal funds, with significant buying and selling activity from large orders [1] Group 2 - Dongyangguang, established on October 24, 1996, is located in Dongguan, Guangdong Province, and was listed on September 17, 1993 [2] - The company's main business segments include electronic new materials (40.81%), chemical new materials (27.63%), electronic components (25.40%), and others [2] - As of September 30, the number of shareholders has increased by 83.12% to 85,400, with an average of 35,128 circulating shares per person, a decrease of 45.39% [2] Group 3 - Dongyangguang has distributed a total of 2.395 billion yuan in dividends since its A-share listing, with 999.8 million yuan distributed in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited is the eighth largest circulating shareholder, increasing its holdings by 11.4531 million shares [3] - The top ten circulating shareholders include Bosera Huixing Return One-Year Holding Period Mixed Fund, which reduced its holdings by 21.7854 million shares [3]

Group 1 - The PVDF concept sector experienced a decline of 3.09%, ranking among the top losers in the market, with companies like Zhongchuang Environmental Protection, Jinming Precision Machinery, and Huitian New Materials showing significant losses [1] - The top gainers in the market included the duty-free shop sector with a rise of 1.44%, while the superconducting concept saw a decline of 3.32% [2] - The PVDF concept sector faced a net outflow of 516 million yuan from major funds, with 16 stocks experiencing net outflows, and 12 stocks seeing outflows exceeding 10 million yuan [3] Group 2 - The stock with the highest net outflow was Duofluor, which saw a net outflow of 264 million yuan and a decline of 3.73% in its stock price [3] - Other notable companies with significant net outflows included Dongyangguang with 37.43 million yuan, Juhua Co. with 34.51 million yuan, and Putailai with 24.95 million yuan [3] - Zhongchuang Environmental Protection had a notable decline of 7.44% with a net outflow of 22.13 million yuan [4]